Skip to content

Celcuity CELC Operating Income

Operating Income at other companies

Gilead Sciences logo
Gilead SciencesGILD
$2.59B+15.6%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$105.96M-1.5%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-$78.59M+7.4%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-$103.61M-38.3%
CG Oncology logo
CG OncologyCGON
-$66.39M-57.3%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$130.25M+12.2%

Other financials

Income statement

See full
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.28B+1,370%
Enterprise value$4.27B+1,086%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celcuity's operating income?
Celcuity (CELC) reported operating income of -$50.51M in Q1 2026.
How has Celcuity's operating income changed year-over-year?
Celcuity's operating income decreased by 39.8% year-over-year, from -$36.13M to -$50.51M.
What is the long-term trend for Celcuity's operating income?
Over 4 years (2021 to 2025), Celcuity's operating income has grown at a 57.0% compound annual growth rate (CAGR), from -$28.36M to -$172.19M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.